102 related articles for article (PubMed ID: 31305121)
21. NKAP functions as an oncogene and its expression is induced by CoCl
Liu J; Wang H; Yin Y; Li Q; Zhang M
Cancer Manag Res; 2018; 10():5091-5100. PubMed ID: 30464609
[TBL] [Abstract][Full Text] [Related]
22. MiR-6875-3p promotes the proliferation, invasion and metastasis of hepatocellular carcinoma via BTG2/FAK/Akt pathway.
Xie Y; Du J; Liu Z; Zhang D; Yao X; Yang Y
J Exp Clin Cancer Res; 2019 Jan; 38(1):7. PubMed ID: 30621734
[TBL] [Abstract][Full Text] [Related]
23. MDA19, a novel CB2 agonist, inhibits hepatocellular carcinoma partly through inactivation of AKT signaling pathway.
Rao M; Chen D; Zhan P; Jiang J
Biol Direct; 2019 May; 14(1):9. PubMed ID: 31053086
[TBL] [Abstract][Full Text] [Related]
24. Knockdown of Ubiquitin Associated Protein 2-Like (UBAP2L) Inhibits Growth and Metastasis of Hepatocellular Carcinoma.
Li Q; Wang W; Hu YC; Yin TT; He J
Med Sci Monit; 2018 Oct; 24():7109-7118. PubMed ID: 30291221
[TBL] [Abstract][Full Text] [Related]
25. HSCs-derived COMP drives hepatocellular carcinoma progression by activating MEK/ERK and PI3K/AKT signaling pathways.
Li Q; Wang C; Wang Y; Sun L; Liu Z; Wang L; Song T; Yao Y; Liu Q; Tu K
J Exp Clin Cancer Res; 2018 Sep; 37(1):231. PubMed ID: 30231922
[TBL] [Abstract][Full Text] [Related]
26. MACC1 suppresses cell apoptosis in hepatocellular carcinoma by targeting the HGF/c-MET/AKT pathway.
Yao Y; Dou C; Lu Z; Zheng X; Liu Q
Cell Physiol Biochem; 2015; 35(3):983-96. PubMed ID: 25660117
[TBL] [Abstract][Full Text] [Related]
27. ACK1 promotes hepatocellular carcinoma progression via downregulating WWOX and activating AKT signaling.
Xie B; Zen Q; Wang X; He X; Xie Y; Zhang Z; Li H
Int J Oncol; 2015 May; 46(5):2057-66. PubMed ID: 25738261
[TBL] [Abstract][Full Text] [Related]
28. Simvastatin induces growth inhibition and apoptosis in HepG2 and Huh7 hepatocellular carcinoma cells via upregulation of Notch1 expression.
Huang X; Ma J; Xu J; Su Q; Zhao J
Mol Med Rep; 2015 Mar; 11(3):2334-40. PubMed ID: 25412322
[TBL] [Abstract][Full Text] [Related]
29. PES1 enhances proliferation and tumorigenesis in hepatocellular carcinoma via the PI3K/AKT pathway.
Wang J; Sun J; Zhang N; Yang R; Li H; Zhang Y; Chen K; Kong D
Life Sci; 2019 Feb; 219():182-189. PubMed ID: 30630006
[TBL] [Abstract][Full Text] [Related]
30. MEG2 inhibits the growth and metastasis of hepatocellular carcinoma by inhibiting AKT pathway.
Ying D; Ruan Y; Zhou X
Gene; 2019 Mar; 687():1-8. PubMed ID: 30399427
[TBL] [Abstract][Full Text] [Related]
31. The long non-coding RNA PTTG3P promotes cell growth and metastasis via up-regulating PTTG1 and activating PI3K/AKT signaling in hepatocellular carcinoma.
Huang JL; Cao SW; Ou QS; Yang B; Zheng SH; Tang J; Chen J; Hu YW; Zheng L; Wang Q
Mol Cancer; 2018 May; 17(1):93. PubMed ID: 29803224
[TBL] [Abstract][Full Text] [Related]
32. miR-505 enhances doxorubicin-induced cytotoxicity in hepatocellular carcinoma through repressing the Akt pathway by directly targeting HMGB1.
Lu L; Zhang D; Xu Y; Bai G; Lv Y; Liang J
Biomed Pharmacother; 2018 Aug; 104():613-621. PubMed ID: 29803174
[TBL] [Abstract][Full Text] [Related]
33. FSTL1 contributes to tumor progression via attenuating apoptosis in a AKT/GSK-3β - dependent manner in hepatocellular carcinoma.
Yang W; Wu Y; Wang C; Liu Z; Xu M; Zheng X
Cancer Biomark; 2017 Jul; 20(1):75-85. PubMed ID: 28655132
[TBL] [Abstract][Full Text] [Related]
34. Rho GDP dissociation inhibitor beta promotes cell proliferation and invasion by modulating the AKT pathway in hepatocellular carcinoma.
Fang Y; Yi J; Lizhi L; Qiucheng C
DNA Cell Biol; 2014 Nov; 33(11):781-6. PubMed ID: 25180836
[TBL] [Abstract][Full Text] [Related]
35. Resveratrol inhibits proliferation and migration through SIRT1 mediated post‑translational modification of PI3K/AKT signaling in hepatocellular carcinoma cells.
Chai R; Fu H; Zheng Z; Liu T; Ji S; Li G
Mol Med Rep; 2017 Dec; 16(6):8037-8044. PubMed ID: 28983625
[TBL] [Abstract][Full Text] [Related]
36. RIP1 upregulation promoted tumor progression by activating AKT/Bcl-2/BAX signaling and predicted poor postsurgical prognosis in HCC.
Wang C; Yao B; Xu M; Zheng X
Tumour Biol; 2016 Nov; 37(11):15305-15313. PubMed ID: 27699664
[TBL] [Abstract][Full Text] [Related]
37. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway.
Huang WC; Tung SL; Chen YL; Chen PM; Chu PY
BMC Cancer; 2018 May; 18(1):609. PubMed ID: 29848298
[TBL] [Abstract][Full Text] [Related]
38. SOX1 functions as a tumor suppressor by antagonizing the WNT/β-catenin signaling pathway in hepatocellular carcinoma.
Tsao CM; Yan MD; Shih YL; Yu PN; Kuo CC; Lin WC; Li HJ; Lin YW
Hepatology; 2012 Dec; 56(6):2277-87. PubMed ID: 22767186
[TBL] [Abstract][Full Text] [Related]
39. Docetaxel promotes cell apoptosis and decreases SOX2 expression in CD133‑expressing hepatocellular carcinoma stem cells by suppressing the PI3K/AKT signaling pathway.
Zhang X; Shao J; Li X; Cui L; Tan Z
Oncol Rep; 2019 Feb; 41(2):1067-1074. PubMed ID: 30483804
[TBL] [Abstract][Full Text] [Related]
40. Nuclear Factor-κB Activating Protein Plays an Oncogenic Role in Neuroblastoma Tumorigenesis and Recurrence Through the Phosphatidylinositol 3-Kinase/Protein Kinase B Signaling Pathway.
Liu J; Zhang M; Kan Y; Wang W; Liu J; Gong J; Yang J
Front Cell Dev Biol; 2020; 8():622793. PubMed ID: 33553160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
